Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice

Behavioural Brain Research

Volumn 154, Issue 2, 2004, Pages 375-383

  Leng, Andreas ^a   Mura, Anna ^a   Hengerer, Bastian ^b   Feldon, Joram ^a   Ferger, Boris ^a,c  

^a ETH ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Behavior; Compensation; Parkinson's disease; Wheel running

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; METIROSINE; NEUROTOXIN; OXYGENASE INHIBITOR; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BIOSYNTHESIS; CADAVER; CONTROLLED STUDY; CORPUS STRIATUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREADMILL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ALPHA-METHYLTYROSINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HOMOVANILLIC ACID; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; RUNNING; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 4143100139     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.03.004     Document Type: Article

References (30)

1. Abercrombie E.D., Bonatz A.E., Zigmond M.J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525:1990;36-44
2. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat. New Biol. 245:1973;150-151
3. Aubin N., Curet O., Deffois A., Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71:1998;1635-1642
4. Ben V., Bruguerolle B. Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study. Life Sci. 67:2000;1549-1558
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455
6. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55:1998;93-116
7. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26:2003;215-221
8. Brogden R.N., Heel R.C., Speight T.M., Avery G.S. Alpha-methyl-p- tyrosine: a review of its pharmacology and clinical use. Drugs. 21:1981;81-89
9. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press, 1997.
10. French T.A., Clay K.L., Murphy R.C., Weiner N. Alpha-methyl-para-tyrosine effects in mice selectively bred for differences in sensitivity to ethanol. Biochem. Pharmacol. 34:1985;3811-3821
11. Freyaldenhoven T.E., Ali S.F., Hart R.W. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688:1995;161-170
12. Garcia-Borreguero D., Larrosa O., Bravo M. Parkinson's disease and sleep. Sleep Med. Rev. 7:2003;115-129
13. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 51:1998;S2-9
14. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-36 [discussion S36-8].
15. Lau Y.S., Fung Y.K. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) on striatal dopamine receptor system. Brain Res. 369:1986;311-315
16. Linder J.C., Klemfuss H., Groves P.M. Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-1236-tetrahydropyridine (MPTP) in mice. Neurosci. Lett. 82:1987;221-226
17. Meissner W., Dovero S., Bioulac B., Gross C.E., Bezard E. Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol. Dis. 13:2003;46-54
18. Mitra N., Mohanakumar K.P., Ganguly D.K. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mice. Brain Res. Bull. 28:1992;355-364
19. Naudin B., Bonnet J.J., Costentin J. Acute L-dopa pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Res. 701:1995;151-157
20. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108:2001;1263-1282
21. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125:2001;109-125
22. Spooren WP, Gentsch C, Wiessner C. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Neuroscience 1998;85:649-51 [discussion 653].
23. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 77:1997;1037-1048
24. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 39:2001;167-174
25. Valentinuzzi V.S., Scarbrough K., Takahashi J.S., Turek F.W. Effects of aging on the circadian rhythm of wheel-running activity in C57BL/6 mice. Am. J. Physiol. 273:1997;R1957-1964
26. Weihmuller F.B., Bruno J.P., Neff N.H., Hadjiconstantinou M. Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse. Eur. J. Pharmacol. 180:1990;369-372
27. Wiener H.L., Lajtha A., Sershen H. Dopamine D1 receptor and dopamine D2 receptor binding activity changes during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Neuropharmacology. 28:1989;535-537
28. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41:1984;856-861
29. Zigmond M.J., Hastings T.G. Neurochemical responses to lesions of dopaminergic neurons: implications for compensation and neuropathology. Adv. Pharmacol. 42:1998;788-792
30. Zigmond M.J., Hastings T.G., Perez R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity. Parkinsonism Relat. Disord. 8:2002;389-393